ROBERT KRANCE to Antineoplastic Agents
This is a "connection" page, showing publications ROBERT KRANCE has written about Antineoplastic Agents.
Connection Strength
0.471
-
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
Score: 0.148
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.148
-
Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001 Jun 01; 19(11):2804-11.
Score: 0.089
-
Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study. Invest New Drugs. 1990 May; 8(2):167-70.
Score: 0.041
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.020
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
Score: 0.013
-
Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. Invest New Drugs. 1986; 4(1):43-8.
Score: 0.008
-
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992; 6 Suppl 2:39-43.
Score: 0.003